Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide

Haematologica

Volumn 95, Issue 1, 2010, Pages 171-172

  Stölzel, Friedrich ^a   Wermke, Martin ^a   Röllig, Christoph ^a   Thiede, Christian ^a   Platzbecker, Uwe ^a   Bornhäuser, Martin ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

All trans retinoic acid; Extramedullary blasts; PML RAR

Indexed keywords

ARSENIC TRIOXIDE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPHOSPHAMIDE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

CANCER RADIOTHERAPY; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; PERIPHERAL BLOOD STEM CELL; PROMYELOCYTIC LEUKEMIA; TREATMENT OUTCOME; ADULT; DRUG ANTAGONISM; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NOTE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; STEM CELL MOBILIZATION;

ADULT; ARSENICALS; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NUCLEAR PROTEINS; OXIDES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, CXCR4; RECEPTORS, RETINOIC ACID; RECURRENCE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 73949136858     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016568     Document Type: Letter

References (10)

1. Montesinos P, Diaz-Mediavilla J, Deben G, Prates V, Tormo M, Rubio V, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal orophylaxis. Haematologica. 2009;94(9): 1242-9.
2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337(15):1021-8.
3. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315-24.
4. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113(9):1875-91.
5. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13(12):1901-28.
6. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19(18):3852-60.
7. Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:391-9.
8. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009;23(1):43-52.
9. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009;113(24):6206-14.
10. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113(23):5720-6.